Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2019-03, Vol.20 (2), p.e133-e136
Hauptverfasser:	Sakamoto, Mandy R., Honce, Justin M., Lindquist, Deborah L., Camidge, D. Ross
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult ALK Anaplastic Lymphoma Kinase - antagonists & inhibitors Antineoplastic Agents - therapeutic use Brigatinib Carcinoma, Non-Small-Cell Lung - drug therapy Central Nervous System - drug effects Central Nervous System - pathology CNS Crizotinib - therapeutic use Drug Approval Humans Lactams, Macrocyclic - therapeutic use Lorlatinib Lung Neoplasms - drug therapy Male Neoplasm Metastasis Organophosphorus Compounds - therapeutic use Pyrimidines - therapeutic use Recurrence Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!